See more : Epsilon Healthcare Limited (EPN.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Blue Jet Healthcare Limited (BLUEJET.NS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Blue Jet Healthcare Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Jupiter Green Investment Trust PLC (JGC.L) Income Statement Analysis – Financial Results
- Viridian Therapeutics, Inc. (VRDN) Income Statement Analysis – Financial Results
- Halo Collective Inc. (HALO.NE) Income Statement Analysis – Financial Results
- NextPlay Technologies, Inc. (NXTP) Income Statement Analysis – Financial Results
- Franchetti S.p.A. (FCH.MI) Income Statement Analysis – Financial Results
Blue Jet Healthcare Limited (BLUEJET.NS)
About Blue Jet Healthcare Limited
Blue Jet Healthcare Limited engages in the manufacturing and sale of pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for applications in pharmaceutical and healthcare products. It provides integrated contrast media intermediates, saccharin and related salts, and niche pharmaceutical intermediates and APIs, as well as CDMO/CMO and development services. Blue Jet Healthcare Limited has operations in India, Norway, the United States, Sweden, Italy, Spain, and internationally. The company was incorporated in 1968 and is headquartered in Thane, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 7.12B | 7.18B | 6.77B | 4.94B | 5.38B |
| Cost of Revenue | 3.20B | 4.48B | 3.80B | 2.47B | 2.10B |
| Gross Profit | 3.91B | 2.70B | 2.97B | 2.47B | 3.28B |
| Gross Profit Ratio | 54.97% | 37.62% | 43.82% | 50.08% | 60.90% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 76.15M | 54.35M | 41.53M | 63.90M | 0.00 |
| Selling & Marketing | 196.35M | 272.65M | 322.79M | 244.33M | 0.00 |
| SG&A | 531.85M | 760.04M | 755.14M | 627.89M | 238.75M |
| Other Expenses | 19.03M | 20.49M | 13.68M | 4.21M | 0.00 |
| Operating Expenses | 531.85M | 739.55M | 741.46M | 623.68M | 1.28B |
| Cost & Expenses | 3.74B | 5.22B | 4.54B | 3.09B | 3.38B |
| Interest Income | 28.18M | 5.87M | 4.38M | 6.16M | 58.06M |
| Interest Expense | 1.61M | 13.59M | 32.80M | 46.89M | 0.00 |
| Depreciation & Amortization | 280.91M | 250.74M | 221.46M | 196.63M | 179.56M |
| EBITDA | 2.48B | 2.43B | 2.69B | 2.15B | 2.19B |
| EBITDA Ratio | 34.90% | 30.82% | 36.14% | 41.44% | 40.62% |
| Operating Income | 3.37B | 1.96B | 2.22B | 1.85B | 2.01B |
| Operating Income Ratio | 47.39% | 27.33% | 32.87% | 37.46% | 37.29% |
| Total Other Income/Expenses | -1.17B | 202.49M | 208.00M | 53.71M | -1.10B |
| Income Before Tax | 2.20B | 2.17B | 2.43B | 1.90B | 1.94B |
| Income Before Tax Ratio | 30.93% | 30.15% | 35.94% | 38.54% | 36.07% |
| Income Tax Expense | 563.44M | 565.84M | 616.39M | 488.70M | 491.68M |
| Net Income | 1.64B | 1.60B | 1.82B | 1.38B | 1.45B |
| Net Income Ratio | 23.01% | 22.27% | 26.83% | 28.01% | 26.91% |
| EPS | 9.44 | 9.23 | 10.47 | 1.43K | 8.35 |
| EPS Diluted | 9.44 | 9.23 | 10.47 | 1.43K | 8.35 |
| Weighted Avg Shares Out | 173.47M | 173.47M | 173.47M | 991.23K | 173.47M |
| Weighted Avg Shares Out (Dil) | 173.47M | 173.47M | 173.47M | 991.23K | 173.47M |
Source: https://incomestatements.info
Category: Stock Reports